Tevogen Bio Holdings Inc (TVGN)

$9.54 -0.28 (-2.85%)
Market Cap 39.82M
Revenue (ttm) 0.00
Net Income (ttm) -26.28M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio -0.65
Volume 25,700
Avg Vol 28,716
Day's Range N/A - N/A
Shares Out 4.19M
Stochastic %K 28%
Beta 0.14
Analysts Hold
Price Target $100.00

Company Profile

Tevogen Bio Holdings Inc., a clinical-stage specialty immunotherapy company, develops off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and other disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment of ambulatory high-risk adult COVID-19 patients; and in Phase 1 clinical trial to treat acute SARS-CoV-2 patients with B-cell cancer immune suppression, and other B cell immune suppressed acute SARS-CoV-2 pat...

Industry: Biotechnology
Sector: Healthcare
Phone: 877 838 6434
Website: tevogen.com
Address:
15 Independence Boulevard, Suite #210, Warren, United States
NGCS
NGCS Jun. 25 at 4:25 PM
$TVGN tic tac … https://x.com/tevogenbio/status/2070154697416077621?s=46
0 · Reply
SuperGreenToday
SuperGreenToday Jun. 17 at 12:03 PM
$TVGN
0 · Reply
NGCS
NGCS Jun. 9 at 8:51 PM
$TVGN Today's PR confirms the master plan is moving fast. The new Healthcare Services division led by VP William Keane is officially created to evaluate and integrate the MSO and CRO acquisitions. CFO Kirti Desai explicitly reiterated the $100M potential combined annual revenue. This isn't just talk; they are building the structure to handle the cash flow before the definitive agreements drop on the SEC.
0 · Reply
NGCS
NGCS Jun. 9 at 8:49 PM
$TVGN Official PR just dropped! 🚨 They officially announced the formation of the Healthcare Services Initiative led by William Keane. Connect the dots people: This is the exact internal corporate infrastructure being built to absorb the MSO & CRO acquisitions. They are literally setting up the house for that incoming $100M annual revenue. Healthy consolidation today holding the $10+ psychological support while shorts tried to play games. The micro-float is locked, the fundamentals are aligning, and the official 8-K contracts signing is the next logical step. 🚀🔥 #Bullish #LowFloat NFA
0 · Reply
focafoca99
focafoca99 Jun. 9 at 7:51 PM
$TVGN created a new healthcare services initiative to explore MSO and CRO acquisitions targeting $100 million in annual revenue.
0 · Reply
NGCS
NGCS Jun. 8 at 10:55 PM
$SUNE congratulations to all shareholders here (x7 today...incredible!!!) Low float here, the same pattern for $TVGN in few weeks (maybe few days). They both low float and a market cap very under-valued. NFA.
0 · Reply
NGCS
NGCS Jun. 8 at 3:36 PM
$TVGN https://x.com/tevogenbio/status/2063987569302343682?s=46
0 · Reply
MakaveliiTime
MakaveliiTime Jun. 8 at 2:23 AM
$CDIO $GNS $JDZG $TVGN $WOLF even if U have a reluctant strategy, w/out executive support your net worth could negatively amount to absolutely nuthin diabolically = -💲💯k+
0 · Reply
NGCS
NGCS Jun. 6 at 4:21 PM
$TVGN Management Tour Highlights: 1️⃣ Vertical Integration: MSO + CRO targets $100M combined revenue path by owning the trial value chain. The "3-in-1" By internalizing clinical trials for the TVGN-489 cell therapy platform, they bypass massive external fees and control the whole value chain. This directly supports the path toward the estimated $100M in combined annual revenue. 2️⃣ Tevogen.AI: PredicTcell moving to commercial stage for Big Pharma licensing. 3️⃣ $3M cash injection at $8 fixed price shows deep insider conviction. 🔥 Yesterday's media blitz wasn't a coincidence. It is a textbook institutional roadshow right before final signatures drop on the definitive agreements. With a tiny 1.09M float completely dried up, the coiled spring is ready to pop into the Annual Shareholder Meeting on June 23rd (IMO). The $10 line has officially flipped from resistance to heavy support. Load, hold, and wait for the SEC 8-K filings! NFA 🚀📈 #LowFloat #Biotech #AI
0 · Reply
robsmi63
robsmi63 Jun. 5 at 8:08 PM
$TVGN acquiring other companies because theirs sucks
0 · Reply
Latest News on TVGN
Tevogen files to sell 375,000 shares of common stock for holders

2026-06-12T21:05:21.000Z - 13 days ago

Tevogen files to sell 375,000 shares of common stock for holders

Tevogen Announces Formation of a Healthcare Services Initiative

Jun 9, 2026, 3:30 PM EDT - 16 days ago

Tevogen Announces Formation of a Healthcare Services Initiative

Tevogen advances strategic acquisition initiatives

2026-05-28T17:30:06.000Z - 4 weeks ago

Tevogen advances strategic acquisition initiatives

Tevogen Advances Strategic Acquisition Initiatives with Potential to Support Approximately $100 Million in Combined Annual Revenue

May 28, 2026, 12:30 PM EDT - 4 weeks ago

Tevogen Advances Strategic Acquisition Initiatives with Potential to Support Approximately $100 Million in Combined Annual Revenue

Tevogen Signs Letter of Intent to Evaluate Potential Acquisition of a Management Services Organization

May 21, 2026, 12:15 PM EDT - 5 weeks ago

Tevogen Signs Letter of Intent to Evaluate Potential Acquisition of a Management Services Organization

Letter to Shareholders from CEO Dr. Ryan Saadi

May 18, 2026, 12:15 PM EDT - 5 weeks ago

Letter to Shareholders from CEO Dr. Ryan Saadi

Tevogen Bio Holdings Inc trading halted, volatility trading pause

2026-05-12T18:10:14.000Z - 6 weeks ago

Tevogen Bio Holdings Inc trading halted, volatility trading pause

Tevogen Bio Holdings Inc trading resumes

2026-05-12T18:07:55.000Z - 6 weeks ago

Tevogen Bio Holdings Inc trading resumes

Tevogen Announces $3 Million Private Investment at $8 Per Share, a 14% Premium from Latest Market Close

May 12, 2026, 11:45 AM EDT - 6 weeks ago

Tevogen Announces $3 Million Private Investment at $8 Per Share, a 14% Premium from Latest Market Close

Tevogen.AI Nears Completion of PredicTcell™ Training; Initiates Commercial Readiness and Debuts Internal Application Portal

Apr 27, 2026, 11:50 AM EDT - 2 months ago

Tevogen.AI Nears Completion of PredicTcell™ Training; Initiates Commercial Readiness and Debuts Internal Application Portal

Tevogen Advances Strategic CRO Evaluation to Expand Clinical Research Delivery Capabilities and Drive Revenue Growth

Mar 26, 2026, 12:45 PM EDT - 3 months ago

Tevogen Advances Strategic CRO Evaluation to Expand Clinical Research Delivery Capabilities and Drive Revenue Growth

Tevogen regains compliance with Nasdaq minimum bid price requirement

2026-03-25T18:25:30.000Z - 3 months ago

Tevogen regains compliance with Nasdaq minimum bid price requirement

Tevogen Regains Compliance with Nasdaq Minimum Bid Price Requirement

Mar 25, 2026, 2:20 PM EDT - 3 months ago

Tevogen Regains Compliance with Nasdaq Minimum Bid Price Requirement

Tevogen CIO and Head of Tevogen.AI Mittul Mehta to Speak at Microsoft Fabric Community Conference (FabCon 2026)

Mar 18, 2026, 12:22 PM EDT - 3 months ago

Tevogen CIO and Head of Tevogen.AI Mittul Mehta to Speak at Microsoft Fabric Community Conference (FabCon 2026)

Tevogen Reaffirms Capital Discipline as Lead Investor Maintains Holdings and Company Limits Share Utilization

Mar 13, 2026, 2:45 PM EDT - 3 months ago

Tevogen Reaffirms Capital Discipline as Lead Investor Maintains Holdings and Company Limits Share Utilization

Tevogen reports performance advancements for Tevogen.AI platform

2026-03-13T16:40:31.000Z - 3 months ago

Tevogen reports performance advancements for Tevogen.AI platform

Tevogen.AI Reports Advancements in PredicTcell™ Beta, Demonstrates Improved Precision Metrics and Expands Proprietary AI Infrastructure

Mar 13, 2026, 12:30 PM EDT - 3 months ago

Tevogen.AI Reports Advancements in PredicTcell™ Beta, Demonstrates Improved Precision Metrics and Expands Proprietary AI Infrastructure

Tevogen CEO Dr. Ryan Saadi Reaffirms Clinical Commitment During International Long COVID Awareness Month; Highlights Synergies of New Leadership Team and Digital Care Platform

Mar 11, 2026, 3:15 PM EDT - 3 months ago

Tevogen CEO Dr. Ryan Saadi Reaffirms Clinical Commitment During International Long COVID Awareness Month; Highlights Synergies of New Leadership Team and Digital Care Platform

Tevogen appoints interim leaders across core business verticals

2026-03-09T11:51:22.000Z - 3 months ago

Tevogen appoints interim leaders across core business verticals

Tevogen Names Leadership Team to Execute Diversified Growth Strategy

Mar 9, 2026, 7:45 AM EDT - 3 months ago

Tevogen Names Leadership Team to Execute Diversified Growth Strategy

Tevogen CEO says ‘actively evaluating potential acquisitions’

2026-03-06T20:45:38.000Z - 3 months ago

Tevogen CEO says ‘actively evaluating potential acquisitions’

Tevogen Bio Holdings Inc trading resumes

2026-03-06T15:20:39.000Z - 3 months ago

Tevogen Bio Holdings Inc trading resumes

Tevogen Bio Holdings Inc trading halted, volatility trading pause

2026-03-06T15:15:32.000Z - 3 months ago

Tevogen Bio Holdings Inc trading halted, volatility trading pause

Tevogen Bio Holdings Inc trading halted, news pending

2026-03-06T00:51:12.000Z - 4 months ago

Tevogen Bio Holdings Inc trading halted, news pending

Tevogen signs LOI to evaluate potential acquisition of Apozeal Pharmaceutical

2026-03-05T20:00:17.000Z - 4 months ago

Tevogen signs LOI to evaluate potential acquisition of Apozeal Pharmaceutical

Tevogen Advances Generics Strategy, Signs Letter of Intent to Evaluate Potential Acquisition of Apozeal Pharmaceutical

Mar 5, 2026, 2:50 PM EST - 4 months ago

Tevogen Advances Generics Strategy, Signs Letter of Intent to Evaluate Potential Acquisition of Apozeal Pharmaceutical

Tevogen downgraded to Hold from Buy at D. Boral Capital

2026-03-04T14:23:36.000Z - 4 months ago

Tevogen downgraded to Hold from Buy at D. Boral Capital

Tevogen announces 50-for-1 reverse stock split

2026-03-04T13:13:07.000Z - 4 months ago

Tevogen announces 50-for-1 reverse stock split

Tevogen Announces Reverse Stock Split

Mar 4, 2026, 8:00 AM EST - 4 months ago

Tevogen Announces Reverse Stock Split

Tevogen signs LoI to evaluate acquisition of contract research organization

2026-02-27T19:25:58.000Z - 4 months ago

Tevogen signs LoI to evaluate acquisition of contract research organization

Tevogen Signs Letter of Intent to Evaluate Potential Acquisition of a Contract Research Organization

Feb 27, 2026, 2:20 PM EST - 4 months ago

Tevogen Signs Letter of Intent to Evaluate Potential Acquisition of a Contract Research Organization

UPDATE - Tevogen Signs Letter of Intent to Evaluate Potential Acquisition of Sciometrix and its Digital Care Management Platform Clinicus

Feb 26, 2026, 4:22 PM EST - 4 months ago

UPDATE - Tevogen Signs Letter of Intent to Evaluate Potential Acquisition of Sciometrix and its Digital Care Management Platform Clinicus

Tevogen signs non-binding LOI to evaluate acquisition of Sciometrix

2026-02-26T14:39:08.000Z - 4 months ago

Tevogen signs non-binding LOI to evaluate acquisition of Sciometrix

Tevogen Signs Letter of Intent to Evaluate Potential Acquisition of Sciometrix and its Digital Care Management Platform Clinicus

Feb 26, 2026, 9:20 AM EST - 4 months ago

Tevogen Signs Letter of Intent to Evaluate Potential Acquisition of Sciometrix and its Digital Care Management Platform Clinicus

Tevogen to evaluate potential one-time special cash dividend

2026-01-30T20:05:31.000Z - 5 months ago

Tevogen to evaluate potential one-time special cash dividend

Tevogen Board to Evaluate Potential One-Time Special Cash Dividend to Shareholders

Jan 30, 2026, 3:00 PM EST - 5 months ago

Tevogen Board to Evaluate Potential One-Time Special Cash Dividend to Shareholders

Tevogen to Align Long-Term Stock-Based Incentive Program With Company Milestones, Including Revenue

Jan 29, 2026, 2:45 PM EST - 5 months ago

Tevogen to Align Long-Term Stock-Based Incentive Program With Company Milestones, Including Revenue

Tevogen reports scientific, operational milestones achieved in 2025

2026-01-12T14:11:33.000Z - 5 months ago

Tevogen reports scientific, operational milestones achieved in 2025

Tevogen Demonstrates Platform Scalability and Multi-Indication T Cell Pipeline Expansion in 2025

Jan 12, 2026, 9:00 AM EST - 5 months ago

Tevogen Demonstrates Platform Scalability and Multi-Indication T Cell Pipeline Expansion in 2025

Tevogen CEO Donates Shares to Support Education for Underprivileged Children

Dec 22, 2025, 12:40 PM EST - 6 months ago

Tevogen CEO Donates Shares to Support Education for Underprivileged Children

Tevogen CEO Donates Personal Shares to Support Local Fire Department

Dec 19, 2025, 11:10 AM EST - 6 months ago

Tevogen CEO Donates Personal Shares to Support Local Fire Department

Tevogen CEO Supports Local Law Enforcement with Personal Contribution of 230,000 Company's Shares of Common Stock

Dec 11, 2025, 3:15 PM EST - 7 months ago

Tevogen CEO Supports Local Law Enforcement with Personal Contribution of 230,000 Company's Shares of Common Stock

Tevogen Celebrates Board Member Dr. Curtis Patton, Honored by Yale University for Distinguished Career and Lasting Contributions to Medical Education and Equity in Medicine

Dec 9, 2025, 2:20 PM EST - 7 months ago

Tevogen Celebrates Board Member Dr. Curtis Patton, Honored by Yale University for Distinguished Career and Lasting Contributions to Medical Education and Equity in Medicine

Tevogen Recognized on 2025 NJBIZ Power List Amid Growth and Multi-Billion-Dollar Revenue Outlook

Dec 8, 2025, 2:50 PM EST - 7 months ago

Tevogen Recognized on 2025 NJBIZ Power List Amid Growth and Multi-Billion-Dollar Revenue Outlook

Tevogen Highlights Continued Capital Efficiency Following Filing of Q3 2025 Form 10-Q

Nov 14, 2025, 2:32 PM EST - 7 months ago

Tevogen Highlights Continued Capital Efficiency Following Filing of Q3 2025 Form 10-Q

Tevogen announces clinical milestone in evolution of ExacTcell platform

2025-11-05T20:25:58.000Z - 8 months ago

Tevogen announces clinical milestone in evolution of ExacTcell platform

Tevogen Reports Major Clinical Milestone: Expands HLA Coverage of its Investigational Precision T Cell Therapy for Acute and Long COVID

Nov 5, 2025, 3:20 PM EST - 8 months ago

Tevogen Reports Major Clinical Milestone: Expands HLA Coverage of its Investigational Precision T Cell Therapy for Acute and Long COVID

Tevogen Clarifies Reported Financials, Highlighting Strong Capital Efficiency and Low Cash Burn

Nov 3, 2025, 2:45 PM EST - 8 months ago

Tevogen Clarifies Reported Financials, Highlighting Strong Capital Efficiency and Low Cash Burn

Tevogen Senior Management Engages with Business and Community Leaders and Highlights Recent Progress

Oct 29, 2025, 12:35 PM EDT - 8 months ago

Tevogen Senior Management Engages with Business and Community Leaders and Highlights Recent Progress

Tevogen Updates on TVGN 489 Following Growing Long COVID Patient Interest

Oct 15, 2025, 3:50 PM EDT - 9 months ago

Tevogen Updates on TVGN 489 Following Growing Long COVID Patient Interest

Tevogen Marks Major Milestone in Its AI Initiative to Enhance Efficacy of T Cell–Based Therapies with 100x PredicTcell™ Beta Data Expansion

Sep 25, 2025, 8:30 AM EDT - 9 months ago

Tevogen Marks Major Milestone in Its AI Initiative to Enhance Efficacy of T Cell–Based Therapies with 100x PredicTcell™ Beta Data Expansion

Tevogen Highlights Potential Role of TVGN 489 in Eliminating Persistent Viral Reservoirs Linked to Long COVID

Sep 23, 2025, 8:30 AM EDT - 9 months ago

Tevogen Highlights Potential Role of TVGN 489 in Eliminating Persistent Viral Reservoirs Linked to Long COVID

Tevogen Commends HHS for Addressing Long COVID, Emphasizes TVGN 489's Potential Impact for 20 Million Americans

Sep 19, 2025, 3:40 PM EDT - 9 months ago

Tevogen Commends HHS for Addressing Long COVID, Emphasizes TVGN 489's Potential Impact for 20 Million Americans

Tevogen CIO and Head of Tevogen.AI Mittul Mehta to Join Startup Forum Panel at Databricks DATA + AI World Tour in Boston

Sep 10, 2025, 11:59 AM EDT - 10 months ago

Tevogen CIO and Head of Tevogen.AI Mittul Mehta to Join Startup Forum Panel at Databricks DATA + AI World Tour in Boston

Tevogen Estimates 5-Year Top-Line Revenue of ∼$6.5 Billion For Product Focused on Liver Cancer Prevention with High-Risk Chronic Hepatitis B Infection

Sep 9, 2025, 3:15 PM EDT - 10 months ago

Tevogen Estimates 5-Year Top-Line Revenue of ∼$6.5 Billion For Product Focused on Liver Cancer Prevention with High-Risk Chronic Hepatitis B Infection

Tevogen Values TVGN-489 at $9–$11 Billion rNPV, Its First Clinical Product From the Proprietary ExacTcell™ Allogeneic T Cell Platform

Sep 8, 2025, 9:27 AM EDT - 10 months ago

Tevogen Values TVGN-489 at $9–$11 Billion rNPV, Its First Clinical Product From the Proprietary ExacTcell™ Allogeneic T Cell Platform

Tevogen Shares Valuation of Key Assets and Potential Forecast For Pipeline Product Focused on EBV Associated Leukemia and Lymphomas

Sep 4, 2025, 3:48 PM EDT - 10 months ago

Tevogen Shares Valuation of Key Assets and Potential Forecast For Pipeline Product Focused on EBV Associated Leukemia and Lymphomas

Tevogen Underscores the Importance of Precision Immunotherapies, Including TVGN 489 for Vulnerable Individuals Infected with SARS-CoV-2

Sep 3, 2025, 4:15 PM EDT - 10 months ago

Tevogen Underscores the Importance of Precision Immunotherapies, Including TVGN 489 for Vulnerable Individuals Infected with SARS-CoV-2

Tevogen Bio Highlights Proprietary Assets and Upcoming Valuation Disclosure

Aug 27, 2025, 3:20 PM EDT - 10 months ago

Tevogen Bio Highlights Proprietary Assets and Upcoming Valuation Disclosure

Tevogen Expresses Gratitude to Yale for Recognition of Dr. Ryan Saadi and Company's Mission of Health Equity

Aug 26, 2025, 2:50 PM EDT - 10 months ago

Tevogen Expresses Gratitude to Yale for Recognition of Dr. Ryan Saadi and Company's Mission of Health Equity

Tevogen Sees Continued Growth in Institutional Ownership in Q2 2025; 72% of Holders Increased or Maintained Positions

Aug 25, 2025, 3:10 PM EDT - 10 months ago

Tevogen Sees Continued Growth in Institutional Ownership in Q2 2025; 72% of Holders Increased or Maintained Positions

Tevogen Recognized in BINJE's BEST Health Care 2025 for Advancing Health Equity and Sustainable Biopharma

Aug 22, 2025, 3:25 PM EDT - 10 months ago

Tevogen Recognized in BINJE's BEST Health Care 2025 for Advancing Health Equity and Sustainable Biopharma

REPEAT -- Tevogen Bio Enters Into Agreement for Up to $50 Million in Financing to Advance R&D and Clinical Development Efforts

Aug 19, 2025, 3:40 PM EDT - 11 months ago

REPEAT -- Tevogen Bio Enters Into Agreement for Up to $50 Million in Financing to Advance R&D and Clinical Development Efforts

Tevogen Delivers Stronger Second Quarter and First Half 2025 Financial Results with Reduced Expenses and Growth Momentum

Aug 19, 2025, 12:10 PM EDT - 11 months ago

Tevogen Delivers Stronger Second Quarter and First Half 2025 Financial Results with Reduced Expenses and Growth Momentum

Tevogen CEO Donates Personal Shares to Support Local Law Enforcement

Aug 18, 2025, 5:50 PM EDT - 11 months ago

Tevogen CEO Donates Personal Shares to Support Local Law Enforcement

Tevogen CEO Donates Personal Shares to Support Brain Injury Recovery

Aug 18, 2025, 5:15 PM EDT - 11 months ago

Tevogen CEO Donates Personal Shares to Support Brain Injury Recovery

Tevogen to Release Internal Asset Valuation; CEO Affirms Assets Are Fully Protected

Aug 14, 2025, 3:55 PM EDT - 11 months ago

Tevogen to Release Internal Asset Valuation; CEO Affirms Assets Are Fully Protected

Repeat - Tevogen.AI Expands Collaboration With Databricks and Microsoft to Build the Beta Version of Its PredicTcell™ Model With a Focus on Oncology

Aug 13, 2025, 3:53 PM EDT - 11 months ago

Repeat - Tevogen.AI Expands Collaboration With Databricks and Microsoft to Build the Beta Version of Its PredicTcell™ Model With a Focus on Oncology

Tevogen Bio Reaffirms Investor Confidence with Estimated Asset Value Exceeding $10 Billion

Aug 11, 2025, 3:45 PM EDT - 11 months ago

Tevogen Bio Reaffirms Investor Confidence with Estimated Asset Value Exceeding $10 Billion

NGCS
NGCS Jun. 25 at 4:25 PM
$TVGN tic tac … https://x.com/tevogenbio/status/2070154697416077621?s=46
0 · Reply
SuperGreenToday
SuperGreenToday Jun. 17 at 12:03 PM
$TVGN
0 · Reply
NGCS
NGCS Jun. 9 at 8:51 PM
$TVGN Today's PR confirms the master plan is moving fast. The new Healthcare Services division led by VP William Keane is officially created to evaluate and integrate the MSO and CRO acquisitions. CFO Kirti Desai explicitly reiterated the $100M potential combined annual revenue. This isn't just talk; they are building the structure to handle the cash flow before the definitive agreements drop on the SEC.
0 · Reply
NGCS
NGCS Jun. 9 at 8:49 PM
$TVGN Official PR just dropped! 🚨 They officially announced the formation of the Healthcare Services Initiative led by William Keane. Connect the dots people: This is the exact internal corporate infrastructure being built to absorb the MSO & CRO acquisitions. They are literally setting up the house for that incoming $100M annual revenue. Healthy consolidation today holding the $10+ psychological support while shorts tried to play games. The micro-float is locked, the fundamentals are aligning, and the official 8-K contracts signing is the next logical step. 🚀🔥 #Bullish #LowFloat NFA
0 · Reply
focafoca99
focafoca99 Jun. 9 at 7:51 PM
$TVGN created a new healthcare services initiative to explore MSO and CRO acquisitions targeting $100 million in annual revenue.
0 · Reply
NGCS
NGCS Jun. 8 at 10:55 PM
$SUNE congratulations to all shareholders here (x7 today...incredible!!!) Low float here, the same pattern for $TVGN in few weeks (maybe few days). They both low float and a market cap very under-valued. NFA.
0 · Reply
NGCS
NGCS Jun. 8 at 3:36 PM
$TVGN https://x.com/tevogenbio/status/2063987569302343682?s=46
0 · Reply
MakaveliiTime
MakaveliiTime Jun. 8 at 2:23 AM
$CDIO $GNS $JDZG $TVGN $WOLF even if U have a reluctant strategy, w/out executive support your net worth could negatively amount to absolutely nuthin diabolically = -💲💯k+
0 · Reply
NGCS
NGCS Jun. 6 at 4:21 PM
$TVGN Management Tour Highlights: 1️⃣ Vertical Integration: MSO + CRO targets $100M combined revenue path by owning the trial value chain. The "3-in-1" By internalizing clinical trials for the TVGN-489 cell therapy platform, they bypass massive external fees and control the whole value chain. This directly supports the path toward the estimated $100M in combined annual revenue. 2️⃣ Tevogen.AI: PredicTcell moving to commercial stage for Big Pharma licensing. 3️⃣ $3M cash injection at $8 fixed price shows deep insider conviction. 🔥 Yesterday's media blitz wasn't a coincidence. It is a textbook institutional roadshow right before final signatures drop on the definitive agreements. With a tiny 1.09M float completely dried up, the coiled spring is ready to pop into the Annual Shareholder Meeting on June 23rd (IMO). The $10 line has officially flipped from resistance to heavy support. Load, hold, and wait for the SEC 8-K filings! NFA 🚀📈 #LowFloat #Biotech #AI
0 · Reply
robsmi63
robsmi63 Jun. 5 at 8:08 PM
$TVGN acquiring other companies because theirs sucks
0 · Reply
NGCS
NGCS Jun. 5 at 6:33 PM
$TVGN https://x.com/tevogenbio/status/2062947502479851900?s=46
0 · Reply
NGCS
NGCS Jun. 5 at 6:32 PM
$TVGN https://x.com/tevogenbio/status/2062934884339863845?s=46
0 · Reply
MrAlientrader
MrAlientrader Jun. 5 at 1:33 PM
$TVGN $100 maybe a bit over optimistic but $50+ is totally reasonable
0 · Reply
Thewolf76
Thewolf76 Jun. 4 at 8:37 PM
$TVGN “TVGN may be one of the most undervalued micro-cap stocks on Nasdaq today. The company is currently valued at only around $35–40 million, yet insiders control approximately 74% of the outstanding shares and the tradable float is extremely small. In other words, very few shares are actually available on the open market. Over the past few months, the company has: * Raised private capital at $8 per share; * Initiated acquisition efforts that could potentially generate up to approximately $100 million in combined annual revenue; * Continued advancing its PredictCell AI platform; * Expanded its Tevogen Generics strategy; * Maintained strong insider ownership without significant insider selling.
1 · Reply
Thewolf76
Thewolf76 Jun. 4 at 8:34 PM
$TVGN buy buy buy
0 · Reply
Thewolf76
Thewolf76 Jun. 4 at 7:47 PM
$TVGN 80% of the shares are in the hands of institutional investors and the owner. Do you have any idea what that means? Everything will explode overnight. We'll be back to $100 in no time. Get in before it's too late and you'll be screwed.
0 · Reply
Thewolf76
Thewolf76 Jun. 4 at 7:44 PM
$TVGN 🚀🚀🚀🪙
0 · Reply
Thewolf76
Thewolf76 Jun. 4 at 7:43 PM
$TVGN this title is ready for takeoff
0 · Reply
MrAlientrader
MrAlientrader Jun. 4 at 7:28 PM
$TVGN short fee 56% on IB means people willing to pay high fee to borrow shares and short. A big buyer then shorts will be screwed
1 · Reply
MrAlientrader
MrAlientrader Jun. 4 at 7:02 PM
$TVGN short interest all time high today, interesting
0 · Reply
Thewolf76
Thewolf76 Jun. 4 at 6:15 PM
$TVGN We will return to $100 very soon, the float is so low that just one small piece of news out of the many that will come out is enough
0 · Reply